Allenex receives part of €2.6M EU grant in collaboration with EUROSTAM

Allenex announces that Allenex group company AbSorber, together with EUROSTAM, a
consortium of European Transplant Centers, has been supported by a € 2.6 million
grant as part of the European Commission 7th framework programme (FP7). This is
part of an ongoing Europe-wide strategy to enhance transplantation of highly
sensitized patients where risk of complication is high due to genetic
mismatches. The main objective of the three year project is to determine the
clinical value of implementing a Europe-wide acceptable HLA mismatch program to
facilitate more as well as safer transplantations on highly sensitized patients
all over Europe.

The XM-ONE crossmatch test, developed by AbSorber, will be used throughout this
project and AbSorber will also develop a modified version of XM-ONE that enables
not only detection of anti-endothelial antibodies, but that can also determine
if the antibodies are complement fixing or non-complement fixing, which might be
another risk factor. XM-ONE crossmatch clinical relevance for highly sensitized
patients will be established. From the €2,6 million grant, AbSorber will receive
€215.000 during the three year period.

“We are proud to be selected as a collaborator into the EUROSTAM consortium.
This is a strong recognition of the product XM-ONE as well as the research and
development done within AbSorber. It is encouraging for our development team to
be recognized for the innovation of XM-ONE”, says Anders Karlsson, CEO of
Allenex and AbSorber. “We look forward to further develop XM-ONE into a
transplantation product with a proven clinical value in cooperation with leading
European transplantation centers”, he concludes.

For more information please contact:
Anders Karlsson, CEO Allenex AB, ph: +4670-918 00 10, e-mail:
anders.karlsson@allenex.se

Allenex AB discloses the information provided herein pursuant to the Securities
Markets Act and /or the Financial Instruments Trading Act. The information was
submitted for publication on Feb 1, 2013, at 10.15 CET. Allenex is a life
science-company that develops, manufacture, market and sell products for safer
transplants of organs and bone marrow on the global market. Allenex is listed on
NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 52 persons are employed in the
Allenex group.